Navigation Links
Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
Date:3/26/2008

BOULDER, Colo., March 26 /PRNewswire-FirstCall/ -- Encision Inc. (Amex: ECI) ("Encision" or the "Company") announced today that it is launching its next generation of EnTouch handles for its AEM(R) articulating laparoscopic instrument inserts.

The new ES8200 and ES8200L handles feature a stiffer shaft design to accommodate the stresses generated by organ manipulation during advanced as well as routine laparoscopic procedures. In addition, the new, easy to operate rotation knob design allows a surgeon to lock the electrode tip in the preferred orientation for the particular need during a laparoscopic procedure. The EnTouch model ES8200 is 35cm in length for normal size patients while the ES8200L is 45cm in length for large patients and many bariatric procedures.

"Our goal is to offer the ultimate in patient safety along with best of class ergonomic instruments for the surgeon performing laparoscopy," said Jack Serino, Encision President & CEO. Handle sales represented approximately 10% of the Company's revenue for its fiscal year ended March 31, 2007.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600,

mmchaffie@encision.com


'/>"/>
SOURCE Encision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
2. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
3. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
4. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
5. Moleac Launches NeuroAid10(TM) in the United States
6. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
7. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
8. BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services
9. ChemAxon Launches Marvin and JChem Version 5: Better User Experience, Better Integration, More Flexibility and Higher Performance
10. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
11. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... , March 22, 2017  UBM and the ... announce their extended partnership and the third annual Massachusetts ... by the 21 st Annual MassMEDIC Conference ... place May 3-4, 2017. MassMEDIC ... Association (ADVAMED) President and CEO, Scott Whitaker ...
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL ... live events series, “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help “no-option” ...
Breaking Biology Technology:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
Breaking Biology News(10 mins):